Logins

Find

Events

Calendars

Technology

More

210-567-7000 Give Search/Quicklinks

Category ID

46

KSAT 12: San Antonio doctor discusses health risks associated with Hill Country floods

KSAT 12: San Antonio doctor discusses health risks associated with Hill Country floods

Share This Story

Read more about KSAT 12: San Antonio doctor discusses health risks associated with Hill Country floods

KABB-TV (Fox San Antonio): New dangers after the flood

KABB-TV (Fox San Antonio): New dangers after the flood

Share This Story

Read more about KABB-TV (Fox San Antonio): New dangers after the flood

WOAI TV (NEWS4SA): New dangers after the flood

WOAI TV (NEWS4SA): New dangers after the flood

Share This Story

Read more about WOAI TV (NEWS4SA): New dangers after the flood

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms (July 8)

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms

Share This Story

Read more about KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms (July 8)

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms (July 9)

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms

Share This Story

Read more about KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms (July 9)

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms (July 10)

KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms

Share This Story

Read more about KSAT 12: If you were injured during the Hill Country floods, watch out for these symptoms (July 10)

Yahoo! Finance: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Yahoo! Finance: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Share This Story

Read more about Yahoo! Finance: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Nasdaq: Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment

Nasdaq: Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment

Share This Story

Read more about Nasdaq: Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment

Benzinga: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Benzinga: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Share This Story

Read more about Benzinga: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Morningstar: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Morningstar: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Share This Story

Read more about Morningstar: Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Subscribe to In the News